The administration said the update to the dashboards is part of its effort to improve transparency around drug pricing; the administration also wants to shift some Part B coverage to Part D as part of its plan to reduce total drug spending, with the idea that Part D plan sponsors would have more negotiating room with pharmaceutical companies.
CMS recently updated its drug spending dashboards with data for 2017, displaying pricing and spending data for thousands of drugs across Medicare Parts B and D and Medicaid.
In 2017, total gross spending on prescription drugs was $154.9 billion in Medicare Part D, $30.4 billion in Part B, and $67.6 billion in Medicaid.
The drug dashboards last updated in May of last year. The administration said it is part of its effort to improve transparency around drug pricing; the administration also wants to shift some Part B coverage to Part D as part of its plan to reduce total drug spending, with the idea that Part D plan sponsors would have more negotiating room with pharmaceutical companies.
The dashboards focus on average spending per dosage unit for prescription drugs and track the change in average spending per dosage unit over time. The web-based tool (or the downloadable spreadsheet, which has more information) can be sorted by manufacturer, drug, price, and more.
“The dashboards pinpoint the sources of rising prescription drug prices to help guide our continued work to address this problem,” said CMS Administrator Seema Verma. She said that, from 2013-2017, prescription drug spending grew at an average annual rate of 10.6% in Medicare Part D, 10% in Part B, and 14.8% in Medicaid.
Verma said in her statement that the tool could be used, for instance, to help doctors and patients compare prices.
However, while the CMS spreadsheets include the number of manufacturers available for a given drug, they do not indicate whether a biosimilar is available for brand-name biologics.
Some of the cost increases for brand-name biologic products include the following:
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
November 8th 2023Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.
BioRationality: FDA Launches a New Opportunity to Remove Redundant Trials of Biosimilars
November 6th 2023The FDA introduced a plan to improve clinical trials, including a provision to possibly eliminate clinical efficacy testing for biologic products, which evidence has suggested may not be necessary, according to Sarfaraz K. Niazi, PhD.